Patients’ time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic

Table 1 Baseline characteristics

Baseline characteristic	All patients, n = 420	TTR < 60%, n = 178	TTR ≥ 60%, n = 242
Age, yr
mean ± SD	65.7 ± 10.9	65.7 ± 10.8	65.7± 10.9
Median (IQR)	67 (15)	66 (14)	67 (15)
Male	227(54.0)	99 (55.6)	128 (52.9)
Female	193 (46.0)	79 (44.4)	114 (47.1)
Ethnicity
Malay	210 (50.0)	96 (53.9)	114 (47.1)
Chinese	179 (42.6)	64 (36.0)	115 (47.5)
Indian	26 (6.2)	16 (9.0)	10 (4.1)
Others	5 (1.2)	2 (1.1)	3 (1.2)
Comorbidities
Diabetes mellitus	170 (40.5)	85 (47.8)	85 (35.1)
Hypertension	291 (69.3)	128 (71.9)	163 (67.4)
Ischemic heart disease	90 (21.4)	48 (27.0)	42 (17.4)
Peripheral vascular disease	8 (1.9)	2 (1.1)	6 (2.5)
Stroke/transient ischemic attack	49 (11.7)	20 (11.2)	29 (12.0)
Deep vein thrombosis/pulmonary embolism	2 (0.5)	1 (0.6)	1 (0.4)
Heart failure	27 (6.4)	12 (6.7)	15 (6.2)
Chronic obstructive pulmonary disease/asthma	22 (5.2)	8 (4.5)	14 (5.8)
Chronic kidney disease	49 (11.7)	28 (15.7)	21 (8.7)
Dyslipidaemia	125 (29.8)	47 (26.4)	78 (32.2)
Chronic rheumatic heart disease	17 (4.0)	10 (5.6)	7 (2.9)
Liver disease	0 (0.0)	0 (0.0)	0 (0.0)
CHA2DS2-VASc score
Mean ± SD	2.6 ± 1.4	-	-
Median (IQR)	3 (1.0)	3 (2)	2(1)
Score 0-1	91 (21.7)	34 (19.1)	57 (23.6)
Score 2-4	297 (70.7)	125 (70.2)	172 (71.1)
Score ≥ 5	32 (7.6)	19 (10.7)	13 (5.4)
HAS-BLED score
Median (IQR)	2 (2.0)	3 (1.0)	2 (2.0)
Low bleeding risk (score ≤ 2)	257 (61.2)	83 (46.6)	174 (71.9)
High bleeding risk (score ≥ 3)	163 (38.8)	95 (53.4)	68 (28.1)

All values are reported as n (%) unless otherwise noted. IQR: Interquartile range; TTR: Time in therapeutic range; SD Standard deviation.